Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 875 mg - amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase-negative) isolates of streptococcus species. (α- and β-hemolytic isolates only), streptococcus pneumoniae , staphylococcus spp., or haemophilus influenzae . amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of escherichia coli, proteus mirabilis , or enterococcus faecalis. amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp., or e. coli. amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), s. pneumoniae, s

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

rebel distributors corp. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 400 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension and chewable tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: lower respiratory tract infections – caused by β-lactamaseproducing strains of h. influenzae and m. catarrhalis. otitis media – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. sinusitis – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. skin and skin structure infections – caused by β-lactamaseproducing strains of s. aureus, e. coli and klebsiella spp. urinary tract infections – caused by β-lactamase-producing strains of e. coli, klebsiella spp. and enterobacter spp. while amoxicillin and clavulanate potassium for oral suspension and chewable tablets are indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to amoxicillin and clavulanate potassium for oral suspensi

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 500 mg - amoxicillin capsules are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus species. (α- and   β-hemolytic isolates only), streptococcus pneumoniae , staphylococcus spp., or haemophilus influenzae . amoxicillin capsules are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of escherichia coli, proteus mirabilis , or enterococcus faecalis . amoxicillin capsules are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp., or e. coli . amoxicillin capsules are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), s. pneum

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 875 mg - amoxicillin and clavulanate potassium tablets, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) are indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: - lower respiratory tract infections – caused by beta–lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis . - acute bacterial otitis media – caused by beta–lactamase–producing isolates of h. influenzae and m. catarrhalis . - sinusitis – caused by beta–lactamase–producing isolates of h. influenzae and m. catarrhalis . - skin and skin structure infections – caused by beta–lactamase–producing isolates of staphylococcus aureus , escherichia coli , and klebsiella species. - urinary tract infections – caused by beta–lactamase–producing isolates of e. coli , klebsiella species, and en

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

actavis new zealand limited - amoxicillin trihydrate 30.3 mg/ml equivalent to 25 mg/ml amoxicillin, on reconstitution;   - powder for oral suspension - 125 mg/5ml - active: amoxicillin trihydrate 30.3 mg/ml equivalent to 25 mg/ml amoxicillin, on reconstitution   excipient: carmellose sodium citric acid colloidal silicon dioxide erythrosine essence btm dm 7020a purified talc sodium benzoate sucrose - amoxicillin is indicated for the treatment of infections due to susceptible organisms. amoxicillin may be useful in instituting therapy prior to bacteriology; however bacteriological studies to determine the causative organisms and their sensitivity to amoxicillin should be determined. amoxicillin may be used for the prevention of bacteraemia, associated with procedures such as dental extraction, in patients at risk of developing bacterial endocarditis.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

actavis new zealand limited - amoxicillin trihydrate 60.26 mg/ml equivalent to 50 mg/ml amoxicillin, on reconstitution;   - powder for oral suspension - 250 mg/5ml - active: amoxicillin trihydrate 60.26 mg/ml equivalent to 50 mg/ml amoxicillin, on reconstitution   excipient: carmellose sodium citric acid colloidal silicon dioxide erythrosine essence btm dm 7020a purified talc sodium benzoate sucrose - amoxicillin is indicated for the treatment of infections due to susceptible organisms. amoxicillin may be useful in instituting therapy prior to bacteriology; however bacteriological studies to determine the causative organisms and their sensitivity to amoxicillin should be determined. amoxicillin may be used for the prevention of bacteraemia, associated with procedures such as dental extraction, in patients at risk of developing bacterial endocarditis.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

american antibiotics,inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin 250 mg - amoxicillin is indicated in the treatment of infections due to susceptible (only β-lactamase-negative) strains of the designated microorganisms in the conditions listed below: infections of the ear, nose, and throat - due to streptococcus spp. (α- and β- hemolytic strains only), s. pneumoniae , staphylococcus spp., or h. influenzae . infections of the genitourinary tract - due to e. coli, p. mirabilis, or e. faecalis . infections of the skin and skin structure - due to streptococcus spp. (α- and β-hemolytic strains only), staphylococcus spp., or e. coli . infections of the lower respiratory tract - due to streptococcus spp. (α- and β-hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae . gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to n. gonorrhoeae (males and females). h. pylori eradication to reduce the risk of duodenal ulcer recurrence. triple therapy amoxicillin/clarithromycin/lansoprazole amoxicillin, in combination with clarithromycin

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

bi-coastal pharma international llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 250 mg - amoxicillin is indicated in the treatment of infections due to susceptible (only β-lactamase-negative) strains of the designated microorganisms in the conditions listed below: infections of the ear, nose, and throat - due to streptococcus spp. (α- and β- hemolytic strains only), s. pneumoniae , staphylococcus spp., or h. influenzae . infections of the genitourinary tract - due to e. coli, p. mirabilis, or e. faecalis . infections of the skin and skin structure - due to streptococcus spp. (α- and β-hemolytic strains only), staphylococcus spp., or e. coli . infections of the lower respiratory tract - due to streptococcus spp. (α- and β-hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae . gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to n. gonorrhoeae (males and females). h. pylori eradication to reduce the risk of duodenal ulcer recurrence. triple therapy amoxicillin/clarithromycin/lansoprazole amoxicillin, in combination with clarithromycin p

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

blenheim pharmacal, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 500 mg - amoxicillin is indicated in the treatment of infections due to susceptible (only β-lactamase-negative) strains of the designated microorganisms in the conditions listed below: infections of the ear, nose, and throat - due to streptococcus spp. (α- and β- hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae . infections of the genitourinary tract - due to e. coli, p. mirabilis , or e. faecalis . infections of the skin and skin structure - due to streptococcus spp. (α- and β-hemolytic strains only), staphylococcus spp., or e. coli . infections of the lower respiratory tract - due to streptococcus spp. (α- and β-hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae . gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to n. gonorrhoeae (males and females). h. pylori eradication to reduce the risk of duodenal ulcer recurrence. triple therapy amoxicillin/clarithromycin/lansoprazole amoxicillin, in combination with clarithromycin pl

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

readymeds - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 500 mg - amoxicillin is indicated in the treatment of infections due to susceptible (only β-lactamase-negative) strains of the designated microorganisms in the conditions listed below: infections of the ear, nose, and throat - due to streptococcus spp. (α- and β- hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae . infections of the genitourinary tract - due to e. coli, p. mirabilis , or e. faecalis . infections of the skin and skin structure - due to streptococcus spp. (α- and β-hemolytic strains only), staphylococcus spp., or e. coli . infections of the lower respiratory tract - due to streptococcus spp. (α- and β-hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae . gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to n. gonorrhoeae (males and females). h. pylori eradication to reduce the risk of duodenal ulcer recurrence. triple therapy amoxicillin/clarithromycin/lansoprazole amoxicillin, in combination with clarithromycin pl